AMCP leaders say PBM reform, new drug pricing models and AI will shape this week’s Nexus meeting in San Diego.
News|Articles|July 1, 2002
Congress expands drug safety surveillance as part of bioterrorism bill
Just before leaving Washington for the Memorial Day recess in May, Congress approved legislation to enhance the ability of hospitals and public health agencies to respond to bioterrorist threats.
Advertisement
Advertisement
Related to this article
Ty Gluckman, M.D., says missed lipid tests and clinical inertia, not prior authorization, are now the main barriers to reaching LDL goals.
Christine Johnston says biosimilar interchangeability bills, plus 2026 PBM reforms, would force PBMs to justify preferring higher-cost brands.
Phase 3 data fueled buzz about Moderna’s personalized melanoma “vaccine.” paired with Merck's Keytruda. The drama surrounding intismeran included an embargo violation and headlines that the treatment hadn't lived up to its hype.
Will Carroll, Pharm.D., of Sutter Health says future pharmacy leaders need business, finance and AI skills, and health systems need real sponsorship.
Will Carroll, Pharm.D., of Sutter Health says pharmacy is often handed strategy to execute instead of shaping it, and must show value in C-suite terms.
Ty Gluckman, M.D., says undertesting and undertreatment are the biggest gaps in lipid care and calls on leaders to invest in cardiovascular prevention.
Ty Gluckman, M.D., says the 2026 dyslipidemia guideline brings back risk-based LDL goals, and clinical inertia, not access, is now the biggest barrier.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Heart data in sleep study predicts atrial fibrillation, heart failure years in advance
2
5 things you should know about intismeran, the Moderna-Merck cancer vaccine
3
Ty Gluckman, M.D., on what the new lipid guidelines mean for payers | HSES 2026
4
Christine Johnston on biosimilar interchangeability and PBM formularies
5